Article

Prognostic Predictors Do Not Equate to Predictors of Chemotherapy Benefit in HR-Positive, HER2-Negative Breast Cancer: A Population-Based Study

2020-10-06

Abstract excerpt

<title>Abstract</title> <p>Background: Patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), early breast cancer had a favorable prognosis. We conducted a study to identify patients benefiting from adjuvant chemotherapy in this cohort. <h4>Methods:</h4> Patients with HR+, HER2-, early breast cancer were identified from the SEER database and were classified into...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e7763eff-a047-57f6-a18e-f8deae760eaa
DOI: 10.21203/rs.3.rs-78025/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Prognostic Predictors Do Not Equate to Predictors of Chemotherapy Benefit in HR-Positive, HER2-Negative Breast Cancer: A Population-Based StudyDOI 10.21203/rs.3.rs-78025/v1Read

Adjuvant Chemotherapy Guidance for pT1-3N0-1 Breast Cancer Patients with HR+, HER2- subtype: a study based on SEER databaseSemantic proximity Read

Development of a Prognostic Model for HR-positive HER2-negative and Node-negative Breast Cancer: Integrating Clinical and Transcriptional BiomarkersSemantic proximity Read

A novel gene signature to predict response to neoadjuvant chemotherapy and endocrine treatment in estrogen receptor-positive breast cancer patientsSemantic proximity Read

Novel Gene Signatures Predictive of Patient Recurrence-free Survival in HR+HER2- Breast CancerSemantic proximity Read

Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancerSemantic proximity Read

Estimated survival outcomes and absolute chemotherapy treatment benefit using PREDICT Tool® and EndoPredict®, in hormone-positive early-stage breast cancer.Semantic proximity Read

Genomic Machine Learning Model Predicts Radiation Therapy Benefit in Early-Stage Breast Cancer Patients with High AccuracySemantic proximity Read

Omission of Chemotherapy in HR+/HER2- Early Invasive Breast Cancer Based on Combined 6-IHC Score?Semantic proximity Read

Novel Immune Subtypes Identification of HER2 Positive Breast Cancer Based On Immunogenomic LandscapeSemantic proximity Read

Identification of immune-related biomarkers for predicting neoadjuvant chemotherapy sensitivity in HER2 negative breast cancer via bioinformatics analysisSemantic proximity Read

Clinically relevant gene signatures provide independent prognostic information in older breast cancer patientsSemantic proximity Read

Novel Prognostic Stratification and Therapeutic Implications in T1N0M0 Breast Cancer: Insights from a Multi-Center Chinese CohortSemantic proximity Read